Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Lentiviral gene therapy developer for tumours and rare diseases
Santo Therapeutics develops in vivo lentiviral gene therapies for cancer and rare genetic disorders. Its proprietary vector platform supports programmes including ST002, an NF2 gene-replacement therapy for NF2-related schwannomatosis. The company announced the start of an investigator-initiated clinical trial of ST002…
Gene therapy platform targeting paediatric solid tumours
Kindling Bio is a biotechnology company developing a gene therapy platform designed specifically for childhood cancers. The platform engineers a biological signal that renders paediatric solid tumours visible to the immune system, enabling immune-mediated destruction across multiple tumour types from a single…
Oral muscle-sparing small molecule therapies for obesity
Hawkhill Therapeutics is a pre-clinical biotechnology company developing oral, muscle-sparing therapeutics for obesity and metabolic health. Its programme targets a clinically validated mechanism to achieve fat-selective weight loss while preserving muscle mass, addressing a recognised limitation of current GLP-1…
AAV gene therapy targeting the seizure focus in refractory epilepsy
Focalis Bio is a biotechnology company developing gene therapies for focal refractory epilepsy, a condition in which seizures arise from a specific brain region and do not respond to antiseizure medicines. Its lead programme, EPY201, is an AAV9-based gene therapy delivered locally via catheter directly to the…
ML-enabled nanoparticle delivery platform for targeted therapeutics
Vector Bioscience is a University of Cambridge spin-out developing a machine learning-enabled drug delivery platform based on metal-organic framework nanoparticles. The technology provides cargo-agnostic, targeted delivery of oligonucleotides and small molecules with controlled release, initially focused on…
RNA therapeutics targeting cellular senescence and age-related disease
Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.…
Proteomics and AI liquid biopsy for early lung cancer detection
Oxford Cancer Analytics is a biotechnology company developing blood-based diagnostic tests for early cancer detection using high-throughput circulating proteome analysis and machine learning. Its platform identifies protein biomarker signatures from blood samples to support clinical decision-making in lung disease,…
Blood-based liquid biopsy for endothelial glycocalyx and microvascular health
Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The…
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders. Its research centres on T14, a 14 amino acid bioactive peptide derived from acetylcholinesterase, which the company has identified as a potential…
Synthetic glucose-binding molecules for continuous glucose monitoring
Carbometrics Limited is a supramolecular chemistry biotech developing synthetic Glucose Binding Molecules (GBMs) for use in continuous glucose monitoring sensors and other diagnostic applications. The GBM platform uses a precisely engineered small-molecule scaffold to selectively bind glucose with high affinity and…
Small-molecule anti-biofilm add-on therapy for antibiotic-resistant urinary tract infections
BioTryp Therapeutics is a UK-based drug discovery company developing small-molecule therapies that inhibit bacterial biofilm formation. The company's lead programme is an oral add-on therapy designed to be used alongside existing antibiotics, targeting a bacterial protein conserved across more than 85 species to…
Blood-based circulating tumour DNA tests for cancer
Inivata is a liquid biopsy company developing molecular tests for cancer using circulating tumour DNA from blood samples. Its sequencing-based assays identify tumour-associated genetic changes and have been used to investigate residual disease, recurrence and treatment response. The technology supports molecular…
Antibody-oligonucleotide conjugates for spatial biology and proteomics
AbOliGo is a biotechnology company developing antibody-oligonucleotide conjugates (AOCs) for multiplexed protein analysis, spatial biology and single-cell workflows. Its conjugation platform addresses a critical bottleneck in multiomic research, as fewer than 0.1% of commercially available antibodies are currently…
Novel gene synthesis technology for faster, lower-cost DNA production
Blue Beagle Bio is an early-stage biotechnology company developing a novel gene synthesis method aimed at delivering faster turnaround times and lower costs compared to existing commercial services. The company targets researchers in academia, SMEs, and the pharmaceutical industry, where access to accurate synthetic…
Antibody therapeutics for inflammatory and autoimmune disease
MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus. Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the…
Developing cell-free long-DNA manufacturing for precision breeding
Newcleic develops cell-free methods for manufacturing long DNA sequences, drawing on biochemical engineering research at UCL. Its technology aims to make complex DNA production more reliable, accessible and sustainable. Its initial focus is agricultural biotechnology, supporting precision breeding and plant…
Yeast-based production platform for veterinary antibody therapeutics
HERlab develops microbial production systems for animal therapeutics using synthetic biology. Its platform applies AI-driven selection across more than a thousand yeast species to match therapeutic proteins with suitable production hosts. It also develops purification technology with veterinary manufacturing costs in…
AI-enabled biologics discovery and therapeutic development
Divergence Labs develops new medicines by combining molecular engineering, machine learning and high-throughput biological experimentation. Its Cambridge research team integrates antibody and biologics discovery, cell engineering and automated screening to identify and optimise therapeutic candidates. Proprietary…
Electrochemical biosensors for biopharmaceutical biosafety and diagnostics
Aureum Diagnostics is a biotechnology company developing electrochemical biosensor platforms for rapid detection of biological and chemical targets. Its technology combines portable readers with disposable test strips and cartridges to measure analytes including nucleic acids and proteins. The company serves…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…